Literature DB >> 22921019

Historical perspectives on myelodysplastic syndromes.

David P Steensma1.   

Abstract

Although Georg Hegel quipped, "We learn from history that we do not learn from history", Aldous Huxley expressed a more nuanced view: "The charm of history and its enigmatic lesson consist in the fact that, from age to age, nothing changes and yet everything is completely different." In order to understand present-day positions and peculiarities in any field of human endeavor, familiarity with the past is essential. Those of us who study myelodysplastic syndromes (MDS) or care for patients diagnosed with these troublesome conditions may wonder also how the current state of affairs evolved with respect to our narrow area of focus, and how we know what we think we know now about these still-enigmatic bone marrow diseases. Here, I review a number of developments that collectively represent a brief "history of MDS." I first highlight a few landmark observations that preceded any concept of MDS by hundreds of years. Twentieth-century case descriptions and series with hypotheses about the etiology and nature of disorders described as "refractory anemia", "preleukemia", and with other terminology culminated in the efforts of the French-American-British (FAB) Co-operative Group of morphologists, whose landmark 1976 and 1982 papers provided the first widely-used classification of MDS. More recent developments in the MDS field include new mechanistic biological insights, regulatory approval of several somewhat-effective treatments, and improved organizational support and advocacy. The history of a disease concept like MDS, as for history in general, provides both inspiration and cautionary tales that can inform present and future work.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22921019     DOI: 10.1016/j.leukres.2012.08.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

Review 1.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

Review 2.  [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].

Authors:  A H Schmitt-Graeff; M J Müller; P Fisch
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

Review 3.  Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.

Authors:  Ali N Chamseddine; Elias Jabbour; Hagop M Kantarjian; Zachary S Bohannan; Guillermo Garcia-Manero
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.945

4.  Editorial: A Revised Approach to the Pathogenesis and Diagnosis of Myelodysplastic Syndromes With Therapeutic Implications.

Authors:  Carmen Mariana Aanei; Lydia Campos Catafal; Denis Guyotat
Journal:  Front Oncol       Date:  2018-07-17       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.